Trial Profile
An Open Label Study on the Effects of a Short Course of SB480848 (Darapladib) on Contents of Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis
- Focus Biomarker; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 16 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
- 18 Apr 2014 New source identified and integrated (United Kingdom Clinical Research Network; 15899).